%PDF-1.4
%
1 0 obj
<>stream
application/pdf
10.1080/14737140.2019.1696676
en
Why do the majority of patients not respond at all, or only partially or transiently, to immunotherapy?
Angus G Dalgleish
Taylor & Francis
Expert Review of Anticancer Therapy, 2019. doi:10.1080/14737140.2019.1696676
immunotherapy
oncology
cancer vaccines
checkpoint inhibitors
biomarkers
Journal
Expert Review of Anticancer Therapy
© 2019 Informa UK Limited, trading as Taylor & Francis Group
1473-7140
1744-8328
0
0
1
10.1080/14737140.2019.1696676
https://doi.org/10.1080/14737140.2019.1696676
AM
2019-11-21T23:06:11+05:30
PScript5.dll Version 5.2.2
2019-11-26T06:57:21-08:00
2019-11-26T06:57:21-08:00
immunotherapy; oncology; cancer vaccines; checkpoint inhibitors; biomarkers
iText 4.2.0 by 1T3XT
uuid:628d4e3d-ec7d-4d2a-a596-da16609e8987
uuid:e184ce5e-4ff7-433f-b18b-ae220dab10ff
2019-11-25truewww.tandfonline.com10.1080/14737140.2019.1696676www.tandfonline.comtrue2019-11-2510.1080/14737140.2019.1696676
endstream
endobj
4 0 obj
<>stream
xYK5ϯCB+t#VYP*W%
zG_OV{M^~~>}nlAt~;NאTUOr[.KThC~cchm{vyP*Y'A[xt-;h%~^\xNcoF qK3 ީ'Ġi4֢Q,>)oy:\Yg|\OYo֬t9KviƧ~W?8mr!0!w@'sϴ$eu=c\& ae](gªY;0+"j$VvMdCKcQR-u&9N˃rYxL]B#F~UM_1~Yi7Ly-bVCݷвq4ekeY,Lh"&{zNZH{?3IPu 8OKH[9V9H4r6B:|!td>ׯ.£;|oLMC0[XCh}TmX䨡:eƷ\
;իG[|CjCC9 n-a>N8shfa#{=1<.w6J+~8WZE@{+=wVF0,цGiRL%R0h$mzi1nғi鉾)ʘv-WXJ[+ϓm\E"O2Lsi^*c+r_.?0lsuHй^'ΧfI;OK:79O@ l"ڒ$O̎%:g,S"\8%k:eKx|/3GjgtF@@N+g2\bK8yLU`2h"YTğl=KV2W->MaO~5W]tM.ڒ=ddP T3N$Q*eSn!+N}.:۠Ӫf[yM̤=&z+8w0m$u;u"+4Rx_Q^Y{䶻puhVGGjګG
3{mfJ/6xN0;=e$W;X߯L~2r{ZF =$:ܕ^c[_/_ǀV&C͑$}DJ<